Aromatherapy essential oil for alleviating insomnia, preparation method and aromatherapy essential oil product and use method

Abstract

This invention relates to the field of compound essential oil technology, specifically to an aromatherapy essential oil for relieving insomnia, its preparation method, aromatherapy essential oil products, and usage methods. The aromatherapy essential oil, by volume, comprises 3-15 parts of a compound plant essential oil and 85-97 parts of a base oil. The compound plant essential oil includes at least two of the following: Bletilla striata essential oil, chamomile essential oil, Pyrola rotundifolia essential oil, Ziziphus jujuba seed essential oil, lavender essential oil, bergamot essential oil, sandalwood essential oil, and vetiver essential oil. The preparation method includes: separately extracting each plant raw material using supercritical CO2 extraction to obtain single essential oils, then mixing them to obtain the compound plant essential oil, and finally mixing it with the base oil. This invention, through the synergistic effect of a specific combination of plant essential oils combined with supercritical CO2 extraction technology to preserve active ingredients, has been demonstrated in animal experiments to significantly improve anxiety behavior, shorten sleep latency, and prolong sleep time in insomnia model animals, exhibiting a clear effect in relieving insomnia. It is safe and convenient to use, providing a new option for the adjunctive treatment of insomnia.

Description

Technical Field

[0001] This invention relates to the field of compound essential oil technology, specifically to an aromatherapy essential oil for relieving insomnia, its preparation method, aromatherapy essential oil products, and its usage. Background Technology

[0002] Insomnia is a common sleep disorder, and long-term insomnia seriously affects people's physical and mental health and quality of life. Currently, the main treatments for insomnia include medication and psychotherapy; however, long-term use of sleeping pills can easily lead to dependence and side effects. Therefore, developing safe, natural, and non-invasive auxiliary treatment methods is of great significance.

[0003] Aromatherapy has a long history of using plant essential oils to promote relaxation and sleep, with lavender essential oil being one of the most widely used. However, the effects of single essential oils are limited, vary from person to person, and there is a lack of synergistic treatment plans for complex insomnia conditions. While there are some attempts at compound essential oils in current technology, the formulations are often arbitrary, lacking scientific experimental data to verify their actual effects, and there is a lack of in-depth research on the synergistic effects between different combinations of plant essential oils, as well as the impact of optimal extraction processes on the activity of active ingredients. For example, essential oils extracted using traditional methods such as steam distillation may suffer from the loss or denaturation of some heat-sensitive active ingredients due to high temperatures, affecting the efficacy of the final product.

[0004] Therefore, providing a compound aromatherapy essential oil with a scientifically formulated recipe that has been experimentally verified to have a significant effect in relieving insomnia and that retains its active ingredients to the maximum extent through a specific process has important practical value. Summary of the Invention

[0005] To address the shortcomings of existing technologies, this invention provides an aromatherapy essential oil for relieving insomnia, its preparation method, the aromatherapy essential oil product, and its usage method. Animal experiments have confirmed that it can significantly improve anxiety behavior, shorten sleep latency, and prolong sleep time in insomnia model animals, demonstrating a clear effect in relieving insomnia and promoting sleep. The product of this invention is safe and convenient to use, providing a new option for the adjunctive treatment of insomnia.

[0006] This invention is achieved through the following technical solution:

[0007] In a first aspect, the present invention provides an aromatherapy essential oil for relieving insomnia, comprising, by volume, 3 to 15 parts of compound plant essential oil and 85 to 97 parts of base oil; wherein: the compound plant essential oil includes at least two of the following: Bletilla striata essential oil, chamomile essential oil, Pyrola rotundifolia essential oil, Ziziphus jujuba var. spinosa essential oil, lavender essential oil, bergamot essential oil, sandalwood essential oil, and vetiver essential oil.

[0008] Through the synergistic effect of specific plant essential oil combinations, combined with extraction processes that maximize the retention of active ingredients, and administered via the respiratory route in a scientifically formulated dosage form, this product can gently regulate the nervous system function in a multi-target manner, thereby relieving insomnia, improving anxiety, and promoting sleep.

[0009] Furthermore, the compound plant essential oil includes jujube seed essential oil and lavender essential oil, with a volume ratio of jujube seed essential oil to lavender essential oil of (4~6):(6~4).

[0010] Furthermore, the compound plant essential oil includes jujube seed essential oil, lavender essential oil and chamomile essential oil, with a volume ratio of (3~5):(5~7):(1~3).

[0011] Preferably, the base oil is at least one of coconut oil, almond oil, jojoba oil, grapeseed oil, and caprylic / capric triglycerides.

[0012] Base oils are inherently stable and mild, and they are well miscible with essential oils. As inert carriers, they not only dilute the essential oils but also enhance the experience when applied topically through their lubricating and moisturizing properties. Furthermore, they promote the stability and absorption of certain fat-soluble active ingredients through their lipid environment.

[0013] Secondly, the present invention provides a method for preparing aromatherapy essential oil for relieving insomnia, comprising the following steps:

[0014] S1. Raw material pretreatment: Wash, dry, and pulverize each plant material at low temperature;

[0015] S2, Extraction: The plant materials crushed in S1 are subjected to CO2 supercritical extraction and filtered to obtain the single essential oils of each plant.

[0016] S3. Mixing: Mix the single plant essential oils obtained in S2 evenly according to the formula volume parts to obtain compound plant essential oil;

[0017] S4. Dilution: Mix the compound plant essential oil obtained in S3 with the corresponding volume parts of base oil evenly to obtain an aromatherapy essential oil that relieves insomnia.

[0018] Furthermore, in S1, the drying temperature is 35~50℃, and the low-temperature pulverization temperature is 4~10℃.

[0019] Furthermore, in S2, the CO2 supercritical extraction conditions are: temperature 35~45℃, pressure 30~45 MPa, and time 1~3h. These mild extraction conditions effectively preserve the heat-sensitive and easily oxidized active ingredients in the essential oils.

[0020] Supercritical CO2 extraction is conducted at relatively low temperatures, utilizing the unique solubility of CO2 in its supercritical state to selectively extract volatile and fat-soluble active ingredients from plants. This process avoids the thermal decomposition, oxidation, or hydrolysis of active ingredients that can occur with the high temperatures of traditional distillation methods. This "gentle extraction" process aims to maximize the preservation of the integrity and originality of the active ingredient profile of the plant materials in the formula, ensuring that the chemical composition of the final product matches its claimed traditional efficacy. This is a key technological principle for guaranteeing product efficacy.

[0021] Thirdly, the present invention provides an aromatherapy essential oil product for relieving insomnia, comprising aromatherapy essential oil for relieving insomnia, wherein the product is a liquid preparation and the volume concentration of the aromatherapy essential oil is 3% to 15%.

[0022] Preparations used by inhalation, such as drops, massage oils, or special liquids for diffusers (such as aromatherapy diffusers, diffuser wood, nose clips, etc.).

[0023] Fourthly, the present invention provides a method of using an aromatherapy essential oil product to relieve insomnia, wherein the product is diffused through a diffuser for the user to inhale, or a nose clip containing drops of the product is worn for the user to inhale naturally.

[0024] Furthermore, the diffuser is placed 0.1 to 1 m away from the nostrils of the person taking the inhalation, and the duration of inhalation is 0.5 to 2 hours, with a frequency of 1 to 2 times per day.

[0025] Furthermore, place the bottom of the nose clip, with the essential oil added, firmly against the nasal septum.

[0026] This invention utilizes inhalation via the respiratory tract, and its principle is based on the pharmacological basis of aromatherapy. After inhalation, the small-molecule, highly volatile active ingredients in essential oils (such as monoterpenes and oxygenated terpenes) can rapidly act on the central nervous system through two main pathways:

[0027] Olfactory pathway: Odor molecules stimulate the olfactory nerve, and the signal is transmitted directly to the limbic system of the brain (especially the amygdala and hippocampus). This is a core brain region that regulates mood, memory and stress response, and can thus quickly and directly affect anxiety and sleep.

[0028] Lung absorption: Some components are absorbed through the alveoli and enter the systemic circulation, which can also produce systemic pharmacological effects.

[0029] This non-invasive, relatively rapid-onset administration method avoids the first-pass effect and gastrointestinal irritation associated with oral medications.

[0030] The beneficial effects of this invention are:

[0031] I. Synergistic Effect and Clear Efficacy: Through extensive screening and experimental verification, this invention has discovered the synergistic effect of specific plant essential oil combinations in relieving insomnia. In particular, the compound with lavender and jujube seed as the core, which can be combined with chamomile and other ingredients, has been shown in animal experiments to significantly improve the spontaneous activity ability and anxiety-like behavior of insomnia model animals, and effectively prolong sleep time, shorten sleep latency, and increase sleep onset rate. The effect is significantly better than that of single essential oils (such as lavender) and other compound combinations, proving its superior effect that is not obvious.

[0032] II. Scientific Processing and Preservation of Active Ingredients: The process employs low-temperature pulverization combined with CO2 supercritical extraction technology to extract essential oils in a low-temperature, inert environment. This minimizes the damage and loss of heat-sensitive and easily oxidized active ingredients (such as certain terpenes and esters), ensuring the integrity and high activity of the functional components in the final product.

[0033] III. Safe to Use and Comfortable Experience: This product is derived from natural plants and is administered externally through inhalation, avoiding the burden on the gastrointestinal tract and liver, ensuring safe use. Diluted in a mild carrier oil, it reduces the irritation of using pure essential oils directly and can be used flexibly through aromatherapy, nasal inhalation, and other methods, providing a comfortable and convenient user experience.

[0034] This invention presents a complete logical chain, from the careful selection of raw materials and synergistic formulation, to the preservation of activity through processing, to ensuring safety through dosage form, and finally to the targeted efficacy pathway. Its effectiveness has been empirically supported by standardized animal behavioral experiments (improving spontaneous activity, reducing anxiety, and prolonging sleep). Therefore, its essence is a composite solution based on the combination of traditional efficacy, modern pharmacology, and formulation science, rather than a single-component single-mechanism approach. This invention utilizes the synergistic effect of a specific combination of plant essential oils, combined with CO2 supercritical extraction technology to maximize the retention of active ingredients. Animal experiments have demonstrated that the product significantly improves anxiety behavior, shortens sleep latency, and prolongs sleep time in insomnia model animals, exhibiting a clear effect in relieving insomnia and promoting sleep. The product of this invention is safe and convenient to use, providing a new option for the adjunctive treatment of insomnia. Attached Figure Description

[0035] Figure 1 This is a comparison chart showing the results of spontaneous activity of mice in open field tests in the embodiments and comparative examples of this invention.

[0036] Figure 2 This is a comparison chart showing the results of the embodiment and the comparative example in the elevated cross maze test of the present invention, specifically the percentage of time to open the arm (OT%) and the percentage of times the arm was opened (OE%).

[0037] Figure 3This is a comparison chart of the sleep latency and sleep duration results of the embodiments and comparative examples in the sodium pentobarbital-induced sleep test of the present invention. Detailed Implementation

[0038] To clearly illustrate the technical features of this solution, the following detailed implementation method will be used to explain the solution.

[0039] Example 1: Lavender-Ziziphus jujuba seed compound essential oil

[0040] (1) Raw material pretreatment: Take 1 kg each of lavender and jujube seed, wash them, remove impurities, and dry them in a forced-air drying process at 45℃. The dried raw materials are then pulverized at a low temperature of 4℃ and passed through a 40-mesh sieve.

[0041] (2) Extraction: The above-mentioned pulverized lavender and jujube seed raw materials were subjected to supercritical CO2 extraction at 40℃ and 40MPa, respectively, for 1.5h. The extracted essential oils were filtered through a 0.22μm filter membrane to obtain lavender essential oil and jujube seed essential oil.

[0042] (3) Compounding: Take 5 parts by volume of lavender essential oil and 5 parts by volume of jujube seed essential oil obtained in step (2), place them in a mixer, and stir and mix at 30 rpm for 20 minutes to obtain compound plant essential oil.

[0043] (4) Dilution: Mix the above 10 parts by volume of compound plant essential oil with 90 parts by volume of coconut oil (as base oil), stir well, and you will get the final aromatherapy essential oil product for relieving insomnia (the volume concentration of compound plant essential oil is 10%).

[0044] A small amount of the compound plant essential oil product from Example 1 was taken and its components were analyzed using GC-MS:

[0045] The GC-MS analysis conditions are as follows:

[0046] Chromatographic column: HP-5MS column (30m×0.32mm×0.25μmm) elastic quartz capillary column;

[0047] Programmed temperature rise: 50℃ held for 5 min, then rise to 250℃ at 5℃ / min and hold for 10 min;

[0048] The injection port temperature is 250℃, the injection method is split injection, the split ratio is 1:20, and the carrier gas is He.

[0049] Column flow rate: 1.5 mL / min;

[0050] MS conditions: EI source, electron energy 70 eV; ion source temperature 230℃; MS quadrupole temperature 150℃; mass scan range 50–550 u; solvent delay 3 min. Analytical results are shown in Table 1.

[0051] Table 1 Chemical composition of compound essential oils 1 52.8600 105242689.4560 73.8631 Trioctyl glyceride 2 17.7958 10362359.5285 7.2727 Linaloyl acetate 3 13.0866 8706069.7785 6.1102 Linalool 4 37.5194 1766437.9487 1.2397 Oleic acid 5 44.5517 1340977.9545 0.9411 2-Hydroxy-3-Octayloxypropyldecanoate 6 22.1445 1218070.7143 0.8549 Caryophyllene 7 18.7857 1160105.3680 0.8142 5-Methyl-2-isopropenyl-4-hexene-1-ol ester of acetic acid 8 10.9580 1119723.3324 0.7859 trans-β-ocimene 9 41.4504 1045730.8566 0.7339 1,3-Dicaprylic acid glyceride 10 47.9563 801131.5259 0.5623 1-Capric-3-Caprylic glyceride 11 15.4326 765074.2273 0.5370 Terpinene-4-ol 12 44.2885 626592.8207 0.4398 2-Hydroxy-3-Octayloxypropyldecanoate 13 34.2121 622010.1166 0.4583 hexadecanoic acid 14 41.1929 460519.3134 0.3232 1,2-Dicaprylic acid glyceride 15 46.4514 460329.5038 0.3231 (Z)-9-Octadecanoic acid-2-hydroxy-1-(hydroxymethyl)ethyl ester 16 13.4700 447827.1399 0.3143 1-Octen-3-Alcohol Ester of Acetic Acid 17 46.0795 409960.4257 0.2877 4-Hexyl-1-(7-methoxycarbonylheptyl)bicyclo[4.4.0]decyl-2,5,7-triene 18 23.1172 308721.5370 0.2167 cis-β-farnesene 19 15.8789 298008.9122 0.2092 α-Terpineol 20 10.5918 277526.1010 0.1948 Eucalyptol 21 43.4760 251727.7500 0.1767 Octyl hexadecanoate 22 43.5962 240685.6039 0.1689 4-Hydroxyoctadecanoate Methyl ester 23 11.3014 220936.7067 0.1551 3,7-Dimethyl-1,3,7-Octatriene 24 23.7123 209510.8020 0.1470 <![CDATA[(1R,2S,6S,7S,8S)-8-isopropyl-1-methyl-3-methylene tricyclo[4.4.0.0 2 , 7 decane]]> 25 10.5232 205732.6896 0.1444 D-Limonene 26 34.5268 191587.4724 0.1345 Icomethylcyclodesiloxane 27 54.4507 183438.9696 0.1287 3-(benzoyloxy)propane-1,2-dimethyldioctanoate 28 49.9990 181488.5320 0.1274 2-(Hepanoyloxy)propane-1,3-dimethyldioctanoate 29 15.0779 179551.2921 0.1260 Inner-shaped borneol 30 21.2690 174378.6902 0.1224 nerol acetate 31 43.3673 173996.3501 0.1221 Trimethylsilane palmitate derivatives 32 45.8163 160424.2201 0.1126 Dioctyl heptaate 33 43.0926 145708.0238 0.1023 3-Hydroxypropyl Palmitate Trimethylsilane Derivative 34 9.2929 135084.7898 0.0948 β-Myrcene 35 47.5615 125944.1920 0.0884 1,3-Didecanoic acid glyceride 36 2.6383 123772.7260 0.0869 9-Octadecanoic acid-2,2,2-trifluoroethyl ester 37 8.9496 119845.5966 0.0841 1-Octen-3-ol 38 15.1751 108209.9717 0.0759 5-Methyl-2-isopropenyl-4-hexen-1-ol 39 26.1613 101246.2629 0.0711 Caryophyllene oxide 40 27.5289 90504.8533 0.0635 τ-juniperol 41 10.1398 83821.0576 0.0588 Hexyl acetate 42 24.5306 80941.6452 0.0568 1,2,3,4,4a,5,6,8a - Octahydro-7-methyl-4-methylene-1-isopropylnaphthalene 43 10.4087 78120.6282 0.0548 1-Methyl-3-isopropylbenzene 44 20.7655 75515.0797 0.0530 (Z)-3,7-Dimethyl-2,6-octadien-1-ol acetate 45 15.6729 66365.3898 0.0466 4-Isopropyl-2-cyclohexene-1-one 46 46.9321 65536.0495 0.0460 4,6,8 (14)-cholestartrate 47 40.3232 63704.2546 0.0447 Oleic acid 48 32.0549 60808.1723 0.0427 Isobutyl octadecyl phthalate 49 14.3397 57361.4310 0.0403 (+)-2-camphene 50 22.5794 54084.3044 0.0380 trans-α-bergamotene 51 12.6117 48469.9154 0.0340 cis-5-vinyltetrahydro-α,α,5-trimethyl-2-furanethanol 52 7.6507 47338.8107 0.0332 (1S)-2,2-dimethyl-3-methylenebicyclo[2.2.1]heptane 53 7.1472 46143.0716 0.0324 3-carene 54 9.5047 41631.9164 0.0292 Butyl butyrate 55 37.9257 37058.8049 0.0260 Stearic acid / octadecanoic acid 56 23.0142 35900.7197 0.0252 Humulusene 57 13.9621 35251.9832 0.0247 (E,Z)-2,6-Dimethyl-2,4,6-Octriene 58 40.1859 33478.6082 0.0235 Butyl heptadecanyl sulfite 59 17.2808 31071.6717 0.0218 3-Isopropylbenzaldehyde 60 9.8651 29503.8990 0.0207 3-carene 61 12.0910 28876.6841 0.0203 trans-furan type linalool oxide 62 11.5932 27013.7082 0.0190 Isoprene 63 29.8405 26643.6973 0.0187 Tetradecanoic acid 64 23.2317 25505.8182 0.0179 2,6,10-Trimethyltridecane 65 17.0004 24332.0847 0.0171 (Z)-3,7-Dimethyl-2,6-octadien-1-ol 66 24.0499 23496.0391 0.0165 2-Methyltridecane 67 19.4609 23194.4154 0.0163 2,4-Decadienal 68 21.0115 22664.5678 0.0159 Cubeene 69 18.5911 22550.8947 0.0158 (1S-endoform)-1,7,7-trimethylbicyclo[2.2.1]hepta-2-ol acetate 70 42.2172 21795.9193 0.0153 2,2'-Methylenebis[6-tert-butyl-4-methylphenol] 71 16.4969 21788.4655 0.0153 (3E,5E)-2,6-dimethyl-3,5,7-octtrien-2-ol 72 22.8540 20590.4383 0.0145 (1S-morphology)-2-methyl-3-methylene-2-(4-methyl-3-pentenyl)bicyclo[2.2.1]heptane 73 28.9594 20480.9597 0.0144 3,8-Dimethylundecane 74 6.9412 20193.4997 0.0142 2-Methyl-5-isopropylbicyclo[3.1.0]-2-hexene 75 8.6578 17827.1063 0.0125 4-Methyl-1-isopropylbicyclo[3.1.0]-2-hexene 76 8.5834 16378.8167 0.0115 4-Methylene-1-isopropylcyclohexene 77 23.8039 16230.7306 0.0114 (1R,5R)-4-methylene-1-((R)-6-methyl-5-hepten-2-yl)bicyclo[3.1.0]hexane 78 18.4367 15653.5264 0.0110 2-Methylundecane 79 11.9022 15348.7904 0.0108 (1α,2β,5α)-2-methyl-5-isopropylbicyclo[3.1.0]-2-hexanol 80 12.9378 11820.1813 0.0083 (Z)-3-Undecene-5-yne 81 9.1556 11685.2282 0.0082 3-Octanone 82 21.4121 11516.8473 0.0081 5-(1,5-Dimethyl-4-hexenyl)-2-methyl-1,3-cyclohexadiene 83 26.9281 10781.6638 0.0076 Epicubetin 84 14.6029 10250.6470 0.0072 2-Hexyl methylpropionate 85 25.1371 9012.4040 0.0063 Hexylpentyl ether 86 22.0529 8987.6586 0.0063 α-pinene sesquiterpenes 87 10.3286 8667.9513 0.0061 lateral cymene 88 13.6760 8503.4100 0.0060 Bromomethyl methyl ether 89 19.8614 7801.3165 0.0055 4-methyl-Tigrate amyl ester 90 17.4124 7467.8228 0.0052 carvone 91 28.5302 7171.8169 0.0050 1,4-Methylenephthalazine, 1,4,4a,5,6,7,8,8a-octahydro-1,4,9,9-tetramethyl 92 9.6649 7160.1258 0.0050 α-Thujone 93 24.6049 7144.6730 0.0050 1-(2,6,6-trimethyl-1-cyclohexenyl)-1-penten-3-one 94 24.3989 6657.3935 0.0047 trans-hydrated sesquiterpene 95 3.8513 5495.7476 0.0039 (Z)-7-methyl-2-decene 96 24.2788 5315.4110 0.0037 Octadecylsulfonyl chloride 97 3.5881 5198.9569 0.0036 Isobutyl acetate 98 15.7645 5126.2374 0.0036 α,α,4-Trimethylbenzyl alcohol 99 5.0530 4817.7199 0.0034 Hexyl hydrogen peroxide 100 20.1475 4566.2712 0.0032 Theanol 101 25.4346 4152.9896 0.0029 (2S,4R)-peppermint-6,8-diene-2-hydroperoxide 102 12.3084 4079.9755 0.0029 2,5-Dihydroxy-3-methyl-6-isopropyl-2,5-cyclohexadiene-1,4-dione 103 23.9183 3897.6694 0.0027 <![CDATA[4,8-dioxatricyclo[5.1.0.0³, 5 octane, 1-methyl-5-isopropyl]]> 104 16.2852 3878.7338 0.0027 (S,E)-2,5-Dimethyl-4-vinyl-2,5-hexadiene-1-ylacetate 105 21.8069 3798.0542 0.0027 (1R,5R)-2-methyl-5-((R)-6-methyl-5-heptene-2-yl)bicyclo[3.1.0]-2-hexene 106 20.4279 3372.5465 0.0024 (E,E)-10-(3,3-dimethylepoxyethyl)-4,8-dimethyl-3,7-decadien-2-one 107 29.3084 3329.0408 0.0023 N-(4-acetamidofuran-3-yl)-2-chloroacetamide 108 18.2650 3268.8914 0.0023 4-Isopropyl-1-cyclohexene-1-formaldehyde 109 19.7069 2976.1579 0.0021 3,3-Dimethylhexane 110 16.9089 2798.6329 0.0020 Endoform-1,7,7-trimethylbicyclo[2.2.1]hepta-2-ol carbamate 111 18.3337 2655.7721 0.0019 Dodecahydro-1H-fluorene 112 16.1193 1931.3700 0.0014 Allyl oxalate 113 19.3064 873.7740 0.0006 1-(3,5-Dimethyl-1-adamantanecarboxyl)aminourea

[0052] Table 1 shows that a total of 113 chemical components were identified, and the retention time, peak area and relative content (area percentage) of each component are provided.

[0053] In-depth analysis of the data shows that:

[0054] The product matrix is ​​clearly defined: the most abundant component is tricaprylic acid glyceride (73.8631%), which is a characteristic component of the selected base oil, coconut oil.

[0055] Detection of active ingredients in essential oils: Although the relative content was low, analysis clearly detected a series of characteristic compounds from plant essential oils such as lavender and jujube seed. These components mainly include linalyl acetate, linalool, and oleic acid, the core components of lavender and jujube seed, as well as terpenes (such as (+)-limonene, myrcene, β-pinene, and trans-caryophyllene) and oxygenated terpenes (such as eucalyptol and alpha-terpineol). Literature indicates that these compounds are often associated with neuromodulatory activities such as sedation and anti-anxiety.

[0056] The GC-MS data demonstrate at the chemical composition level that the preparation method can successfully yield the expected product, establishing a characteristic chemical fingerprint for the final product and providing more precise characterization. The identified active ingredients provide a direct material basis for the claimed efficacy of this product in "relieving insomnia and improving anxiety" (see subsequent experimental examples). Through the preparation method of Example 1 of this invention, a compound aromatherapy essential oil product with coconut oil as a base, rich in linalyl acetate, linalool, oleic acid, and specific terpenoids and oxygenated terpenoids, was successfully obtained. This chemical composition is the intrinsic basis for its physiological efficacy verified in subsequent experimental examples.

[0057] Example 2: Lavender-Jujube Seed-Chamomile Compound Essential Oil

[0058] (1) Raw material pretreatment: Take 1 kg each of lavender, jujube seed and chamomile, wash them, remove impurities and dry them in a forced-air drying at 45℃. The dried raw materials are then pulverized at low temperature at 4℃ and passed through a 40-mesh sieve.

[0059] (2) Extraction: Same as step (2) in Example 1, to obtain single essential oils of lavender, jujube seed and chamomile respectively.

[0060] (3) Compounding: Take 5 parts by volume of lavender essential oil, 3 parts by volume of jujube seed essential oil and 2 parts by volume of chamomile essential oil obtained in step (2), mix them evenly to obtain compound plant essential oil.

[0061] (4) Dilution: Same as step (4) in Example 1, to obtain the final product of aromatherapy essential oil (wherein the volume concentration of compound plant essential oil is 10%).

[0062] Example 3: Lavender-Chamomile-Pyrola rotundifolia-Ziziphus jujuba seed compound essential oil

[0063] (1) Raw material pretreatment: Take 1 kg each of lavender, chamomile, deer antler grass and jujube seed, wash them, remove impurities and dry them in a forced-air drying at 45℃. The dried raw materials are then pulverized at low temperature at 4℃ and passed through a 40-mesh sieve.

[0064] (2) Extraction: Same as step (2) in Example 1, to obtain single essential oils of lavender, chamomile, deer antler oil and jujube seed oil respectively.

[0065] (3) Compounding: Take 3 parts by volume of lavender essential oil, 2 parts by volume of chamomile essential oil, 2 parts by volume of deer antler essential oil and 3 parts by volume of jujube seed essential oil obtained in step (2), mix them evenly to obtain compound plant essential oil.

[0066] (4) Dilution: Mix the above 5 parts by volume of compound plant essential oil with 95 parts by volume of coconut oil (as base oil), stir well, and you will get the final aromatherapy essential oil product for relieving insomnia (the volume concentration of compound plant essential oil is 5%).

[0067] Example 4: Lavender-Jujube Seed-Bergamot Compound Essential Oil

[0068] (1) Raw material pretreatment: Take 1 kg each of lavender, jujube seed and bergamot, wash them, remove impurities and dry them in a forced-air drying at 45℃. The dried raw materials are then pulverized at low temperature at 4℃ and passed through a 40-mesh sieve.

[0069] (2) Extraction: Same as step (2) in Example 1, to obtain single essential oils of lavender, jujube seed, and bergamot.

[0070] (3) Compounding: Take 5 parts by volume of lavender essential oil, 3 parts by volume of jujube seed essential oil and 2 parts by volume of bergamot essential oil obtained in step (2), mix them evenly to obtain compound plant essential oil.

[0071] (4) Dilution: Mix the above 15 parts by volume of compound plant essential oil with 85 parts by volume of coconut oil (as base oil), stir well, and you will get the final aromatherapy essential oil product for relieving insomnia (the volume concentration of compound plant essential oil is 15%).

[0072] Comparative Example 1: Single Lavender Essential Oil

[0073] The preparation method is the same as in Example 1, except that in step (3), only 10 parts by volume of lavender essential oil is used and it is not mixed with jujube seed essential oil. In step (4), it is mixed with 90 parts by volume of coconut oil.

[0074] Comparative Example 2: Extraction of Compound Essential Oils by Distillation

[0075] The raw materials are the same as in Example 1. The difference is that step (2) extraction is changed to steam distillation: the crushed raw materials are put into a distillation pot with water, heated and distilled for 4 hours, the distillate is collected, and the oil and water are separated to obtain the single essential oil. Subsequent steps (3) and (4) are the same as in Example 1.

[0076] Comparative Example 3: Commercially available single essential oils

[0077] The essential oils used were commercially available lavender essential oil and jujube seed essential oil, and the other oils were the same as in Example 1.

[0078] Experimental Example: Effects of Aromatherapy Essential Oils on Behavior and Sleep in Insomnia Model Mice

[0079] Experimental animals and grouping: Male ICR mice (5 weeks old). All mice were randomly grouped according to body weight, including a control group, a model group, Example 1 group, Example 2 group, Example 3 group, Example 4 group, Comparative Example 1 group, Comparative Example 2 group, and Comparative Example 3 group. Each group contained 5 mice, for a total of 45 mice. Except for the control group, all groups underwent intraperitoneal injection of p-chlorophenylalanine (PCPA) for 3 days to establish the experimental model. The final grouping was determined using a sodium pentobarbital sleep experiment.

[0080] All mice were kept in the same environment with a 12 / 12h light / dark cycle, at room temperature (20±2)℃, relative humidity 50%-65%, and good ventilation, with free access to food and water.

[0081] Solution:

[0082] (1) Control group: Normal feeding, and 20 μL of pure coconut oil was inhaled (through a diffuser) for 30 minutes. Treatment was carried out once a day, simultaneously with other treatment groups.

[0083] (2) Model group: After modeling, 20 μL of pure coconut oil was inhaled (through a diffuser) for 30 minutes. Treatment was given once a day.

[0084] (3) Example 1 group: After modeling was completed, 20 μL of the essential oil prepared in Example 1 was inhaled (diffuser) for 30 minutes. Treatment was performed once a day.

[0085] (4) Example 2 group: The processing method is the same as that of Example 1 group, and the essential oil prepared in Example 2 is used.

[0086] (7) Comparative Example 1: The treatment method is the same as that of Example 1, using a 10% dilution of the single essential oil prepared in Comparative Example 1.

[0087] (8) Comparative Example 2: The treatment method is the same as that of Example 1, and the essential oil prepared by Comparative Example 2 is used.

[0088] (9) Comparative Example 3: The treatment method is the same as that of Example 1, using the essential oil prepared by Comparative Example 3.

[0089] Test metrics and methods:

[0090] 1. Open field experiment (testing autonomous activities)

[0091] After 6 consecutive days of uninterrupted treatment, the mice were tested 2 hours after treatment on the 6th day. All mice were allowed to acclimatize to the test environment for 3 hours before testing. Each group of mice was placed in an open field test chamber, and after acclimatization for 2 minutes, the total distance traveled, average speed, and time taken to traverse the central area were recorded over 5 minutes. During testing, any interference from the previous mouse's odor or other lingering odors was eliminated.

[0092] 2. Elevated Cross Maze Experiment (for testing anxiety-like behaviors)

[0093] After 7 days of continuous treatment, testing was conducted on day 8. Mice were allowed 3 hours of acclimatization before testing. The mice were placed on the central platform of the maze, and their behavioral parameters were recorded over 5 minutes, including: number of entries into the open arm (OE), number of entries into the closed arm (CE), time spent in the open arm (OT), and time spent in the closed arm (CT). The percentage of entries into the open arm (OE% = OE / (OE+CE)×100%) and the percentage of time spent in the open arm (OT% = OT / (OT+CT)×100%) were calculated as anxiety assessment parameters.

[0094] 3. Sodium pentobarbital-induced sleep experiment

[0095] Suprathreshold dose experiment (testing sleep latency and duration): After 7 consecutive days of treatment, 1 hour after the last treatment, sodium pentobarbital solution (50 mg / kg) was injected intraperitoneally. The time when the righting reflex disappeared (sleep latency) and the time from disappearance to recovery (sleep duration) were observed and recorded.

[0096] Subthreshold dose experiment (testing sleep onset rate): After 7 consecutive days of treatment, on the 8th day, a subthreshold dose of sodium pentobarbital solution (36 mg / kg) was injected intraperitoneally. The animals were observed for 30 minutes, and sleep was defined as the disappearance of the righting reflex for more than 1 minute. The number of animals that fell asleep in each group was counted and the sleep onset rate was calculated.

[0097] Statistical analysis:

[0098] like Figures 1-3 As shown, the experimental data are expressed as mean ± standard deviation, and appropriate statistical software was used for data analysis. # This indicates that the model group is compared to the blank group. # This indicates that p < 0.05; ## This indicates that p < 0.001; ### * indicates p < 0.001; * indicates p < 0.05 compared to the model group, and ** indicates p < 0.01.

[0099] 1. Effects on spontaneous activity in mice (open field experiment)

[0100] The test data results for each group are shown in Table 2 below:

[0101] Table 2 Open Field Test Data Blank group 15.84±1.49 4132.89±218.28 32.50±2.02 Model group <![CDATA[10.19±1.00 ### ]]> <![CDATA[2999.87±179.57 ### ]]> <![CDATA[19.88±2.86 ### ]]> Example 1 Group <![CDATA[13.23±1.18 * ]]> <![CDATA[3729.62±75.12 * ]]> <![CDATA[29.67±2.38 * ]]> Example 2 group <![CDATA[14.02±0.44 ** ]]> <![CDATA[3857.74±174.17 ** ]]> <![CDATA[30.10±1.74 * ]]> Comparative Example 1 9.37±0.56 2857.31±217.46 23.21±3.81 Comparative Example 2 9.97±1.74 2954.11±226.07 24.95±2.52 Comparative Example 3 Groups 10.17±1.25 3025.00±200.10 24.03±4.23

[0102] from Figure 1 As shown in Table 2, the results indicate that, compared with the control group, all three indicators in the model group showed a highly significant decrease, suggesting that the autonomous activity ability of the model animals was significantly impaired, and the model was successfully constructed. Compared with the model group, the three indicators in Example 1 and Example 2 groups showed a significant rebound, with the average speed and behavioral time indicators in Example 1 and 2 groups showing significant improvement. However, the three indicators in Comparative Examples 1, 2, and 3 groups showed no significant difference compared with the model group, and did not show any improvement effect on the abnormal autonomous activity ability of the model animals.

[0103] 2. Effects on anxiety-like behavior in mice (elevated cross maze test)

[0104] The test data results for each group are shown in Table 3 below:

[0105] Table 3. Test data for the elevated cross maze Blank group 31.44±3.27 23.47±2.18 Model group 22.42±1.58 20.10±0.89 Example 1 Group <![CDATA[32.17±1.11 ** ]]> <![CDATA[24.92±0.82 ** ]]> Example 2 group <![CDATA[30.13±0.93 ** ]]> <![CDATA[23.08±1.07 * ]]> Comparative Example 1 22.09±2.90 20.69±1.11 Comparative Example 2 22.48±0.57 19.76±2.44 Comparative Example 3 Groups 25.30±2.00 19.20±1.57

[0106] from Figure 2 As shown in Table 3, the OT% and OE% of the model group decreased significantly compared to the blank group, indicating successful modeling. The Example 1 and Example 2 groups significantly improved the OT% and OE% of the model group, with the Example 1 group showing the most significant improvement, with its OT% even slightly higher than the blank group and its OE% reaching the highest level among all groups. In contrast, the Comparative Examples 1, 2, and 3 groups showed only slight improvements in OT% and OE%, far less effective than the Example 1 groups, indicating that the Example 1 groups in this study can more effectively improve the changes in the corresponding indicators of the model.

[0107] 3. Effects of sodium pentobarbital on sleep-inducing effects

[0108] 3.1 Effects of suprathreshold doses of sodium pentobarbital on sleep-inducing effects

[0109] The test data results for each group are shown in Table 4 below:

[0110] Table 4. Data from sodium pentobarbital-induced sleep test in mice Blank group 4.33±0.58 28.00±1.00 Model group <![CDATA[6.67±0.58 ### ]]> <![CDATA[13.67±1.53 ### ]]> Example 1 Group <![CDATA[3.67±1.15 ** ]]> <![CDATA[38.67±1.53 ** ]]> Example 2 group <![CDATA[4.00±1.00 ** ]]> <![CDATA[35.00±2.65 ** ]]> Comparative Example 1 5.33±0.58 17.00±1.00 Comparative Example 2 6.00±1.00 19.33±1.53 Comparative Example 3 Groups 5.67±1.15 15.00±2.00

[0111] from Figure 3 As shown in Table 4, compared with the control group, the model group had a significantly prolonged sleep latency and a significantly shortened sleep duration, indicating that the sleep disorder model was successfully constructed. Compared with the model group, Examples 1 and 2 significantly shortened sleep latency and prolonged sleep duration. Although Comparative Examples 1, 2, and 3 had some improvement effects, the effects were weaker than those of Examples 1 and 2. Moreover, the improvement of the comparative examples did not reach the same level as that of the examples. This indicates that the intervention of the examples was significantly better than that of the comparative examples in improving sleep disorders and promoting sleep, and had a better sleep-promoting effect.

[0112] 3.2 Effect of subthreshold doses of sodium pentobarbital on sleep onset rate

[0113] The test data results for each group are shown in Table 5 below:

[0114] Table 5. Data on the sleep rate in mice induced by sodium pentobarbital (7 days) Blank group 33.12±1.25 Model group 8.25±2.33 Example 1 Group <![CDATA[97.67±2.52 ** ]]> Example 2 group <![CDATA[96.67±1.53 ** ]]> Comparative Example 1 45.67±4.16 Comparative Example 2 34.67±2.52 Comparative Example 3 Groups 15.33±4.16

[0115] As can be seen from the results in Table 5, the sleep onset rate was 33.12% in the blank group and 8.25% in the model group when injected with subthreshold doses of sodium pentobarbital. After treatment in the Example 1 and Example 2 groups, the sleep onset rate was close to 100%, which can significantly improve the sleep onset rate of the model animals. In contrast, the control groups 1 to 3 can only slightly improve the sleep onset rate, and the effect is much weaker than that of the Example groups. This indicates that the Example regimens tested in this study have excellent sleep-inducing activity and are significantly better than the control regimens.

[0116] The above experimental results show that the compound aromatherapy essential oil of this invention, prepared by CO2 supercritical extraction, has significant and synergistic effects in improving anxiety behavior, promoting spontaneous activity, shortening sleep onset time, prolonging sleep duration, and increasing sleep onset rate in insomnia model mice. Its effects are significantly superior to Comparative Example 1 (single lavender), Comparative Example 2 (compound extracted by traditional distillation), and Comparative Example 3 (commercially available essential oil). This demonstrates that the specific plant essential oil combination in this invention (with lavender and jujube seed as the core) and its compound product prepared by CO2 supercritical extraction have a synergistic effect in relieving insomnia, exhibiting outstanding beneficial effects. The rapid sedative and relaxing effects of lavender essential oil (mainly containing linalool, linalyl acetate, etc.), combined with the heart-nourishing and calming effects of jujube seed essential oil (traditionally used for calming the nerves), may produce a synergistic effect of "1+1>2" by acting on different targets or signaling pathways of the neurotransmitter system (such as GABA and 5-HT). The addition of chamomile essential oil (containing magnolia oleracea, etc.) may further enhance its anti-inflammatory and anti-anxiety effects. This specific compound, which has been screened and validated, is the core innovation and the basis of the effectiveness of this invention.

Claims

1. An aromatherapy essential oil for alleviating insomnia, characterized by: By volume, it includes 3 to 15 parts of compound plant essential oil and 85 to 97 parts of base oil; wherein: the compound plant essential oil includes at least two of the following: Bletilla striata essential oil, Chamomile essential oil, Pyrola rotundifolia essential oil, Ziziphus jujuba var. spinosa essential oil, Lavender essential oil, Bergamot essential oil, Sandalwood essential oil, and Vetiver essential oil.

2. The aromatherapy essential oil for alleviating insomnia according to claim 1, characterized in that: The compound plant essential oils include jujube seed essential oil and lavender essential oil, with a volume ratio of (4~6):(6~4) between jujube seed essential oil and lavender essential oil.

3. The aromatherapy essential oil for alleviating insomnia according to claim 1, characterized in that: In compound plant essential oils, lavender essential oil contains no less than 30% linalyl acetate and no less than 24% linalool; jujube seed essential oil contains no less than 17% oleic acid.

4. The aromatherapy essential oil for alleviating insomnia according to claim 1, characterized in that: The base oil is at least one of coconut oil, almond oil, jojoba oil, grapeseed oil, and caprylic / capric triglycerides.

5. The method for preparing aromatherapy essential oil for relieving insomnia according to any one of claims 1 to 4, characterized in that: Includes the following steps: S1. Raw material pretreatment: Wash, dry, and pulverize each plant material at low temperature; S2, Extraction: The plant materials crushed in S1 are subjected to CO2 supercritical extraction and filtered to obtain the single essential oils of each plant. S3. Mixing: Mix the single plant essential oils obtained in S2 evenly according to the formula volume parts to obtain compound plant essential oil; S4. Dilution: Mix the compound plant essential oil obtained in S3 with the corresponding volume parts of base oil evenly to obtain an aromatherapy essential oil that relieves insomnia.

6. The method for preparing the aromatherapy essential oil for relieving insomnia according to claim 5, characterized in that: In S1, the drying temperature is 35~50℃, and the low-temperature pulverization temperature is 4~10℃.

7. The method for preparing the aromatherapy essential oil for relieving insomnia according to claim 5, characterized in that: In S2, the supercritical CO2 extraction conditions are: temperature 35~45℃, pressure 30~45 MPa, and time 1~3h.

8. An aromatherapy essential oil product for alleviating insomnia, comprising the aromatherapy essential oil for alleviating insomnia according to any one of claims 1 to 3, characterized by: The product is a liquid preparation, in which the volume concentration of aromatherapy essential oil is 3% to 15%.

9. A method of using the aromatherapy essential oil product for alleviating insomnia according to claim 8, characterized in that: The product can be diffused through a diffuser for users to inhale, or a nose clip containing the product can be worn for users to inhale naturally.

Images